Medical/Pharmaceuticals APAC News & Press Release Distribution

Medical/Pharmaceuticals

All
Global

Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus

Recommendation will enable eligible patients in England, Wales and Northern Ireland to access the first licensed treatment for moderate-to-severe chronic kidney disease (CKD)-associated pruritus in adult patients on haemodialysis ST. GALLEN, Switzerland and STAMFORD, Conn., May 18, 2023 /PRNewswi...

2023-05-18 14:00 3316

Antengene Announces Clearance of U.S. IND for the Phase I Trial of First-in-Class Anti-CD24 Monoclonal Antibody ATG-031

* ATG-031, discovered and developed in-house by Antengene, is the world's first anti-CD24 antibody to advance to the clinic in oncologyand Antengene's third drug candidate to enter clinical studies in the U.S. * The Phase I "PERFORM" study will evaluate the safety and tolerability, pharmacolo...

2023-05-18 11:53 2875

Gleneagles Hospital Kuala Lumpur Applauded by Frost & Sullivan for Its Initiatives in Improving the Patient Experience and Customer Value

Gleneagles is among the few hospitals in Malaysia that continually invests in clinical data solutions to improve patient outcomes using procedural clinical data. SAN ANTONIO, May 18, 2023 /PRNewswire/ -- Frost & Sullivan recently assessed the healthcare industry and, based on its findings, recog...

2023-05-18 10:13 2141

Gleneagles Hospital Kuala Lumpur Applauded by Frost & Sullivan for Its Initiatives in Improving the Patient Experience and Customer Value

Providence-based "Biotech start up" EpiVax Celebrates 25th Anniversary

PROVIDENCE, R.I., May 17, 2023 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") is celebrating its 25th birthday by renewing the company's commitment to improving human health everywhere while highlighting the development of groundbreaking tools by the company. In addition, EpiVax is celebrating the work ...

2023-05-17 23:49 2305

Sirnaomics to receive HK$8 million subsidy from the HKSTP Clinical Translational Catalyst Plan

HONG KONG and GERMANTOWN, Md. and SUZHOU BIOBAY, China, May 17, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company"; together with its subsidiaries, the"Group" or "Sirnaomics"; stock code: 2257), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeuti...

2023-05-17 21:13 2805

Insilico Medicine Successfully Explores the Advantages of Quantum Generative Adversarial Networks in Generative Chemistry

NEW YORK, May 17, 2023 /PRNewswire/ -- Insilico Medicine, a clinical stage generative artificial intelligence (AI)-driven drug discovery company, today announced that it groundbreakingly combines two rapidly developing technologies, quantum computing and generative AI to explore the lead candidat...

2023-05-17 18:00 2851

Parliamentarians from 23 countries call on G7 leaders to invest in neglected tropical diseases

Uniting to Combat Neglected Tropical Diseases (unitingtocombatntds.org) releases letter signed by 36 Parliamentarians from 23 countries calling on G7 Leaders to invest in NTDs. LONDON, May 17, 2023 /PRNewswire/ -- To: Fumio Kishida, Prime Minister, Japan (Host) Joe Biden, President, United Stat...

2023-05-17 17:40 2567

Inclusion of Recbio In the MSCI China Small Cap Index

TAIZHOU, China, May 17, 2023 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that, MSCI announced the results of the semi-annual review of the MSCI Global Small Cap Indexes onMay 12, 2023, and the Company has ...

2023-05-17 14:01 5489

Antengene Announces NDA Submission for XPOVIO® in Indonesia

SHANGHAI and HONG KONG, May 17, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hema...

2023-05-17 08:30 2615

Transcenta Announces Encouraging Phase I Clinical Data of TST002 (Blosozumab) in Chinese Patients with Reduced Bone Mineral Density

SUZHOU, China, May 17, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics,announces encouraging phase I cl...

2023-05-17 08:17 2160

Innovent Announces Clinical Data of Multiple Trials Will be Presented at the 2023 ASCO and EHA Annual Meetings

ROCKVILLE, Md. and SUZHOU, China, May 17, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and...

2023-05-17 08:00 4119

Everest Medicines Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Etrasimod in Asia

SHANGHAI, May 17, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today the completion of patient enrollment in a multi-...

2023-05-17 07:48 3637

DEBIOPHARM LAUNCHES PHASE 1/2 COMBINATION TRIAL INVESTIGATING BRAIN-PENETRANT SELECTIVE WEE1 INHIBITOR FOR BRAIN CANCER PATIENTS

* Glioblastomas (GBM) are among the most aggressive and lethal tumors of the central nervous system with a 5-year survival rate of only 6.8%. * Debiopharm is combining its potent, brain penetrant WEE1 inhibitor Debio 0123 with standard of care (SOC) therapy. Debio 0123 hopes to hinder DNA dama...

2023-05-17 07:00 2054

Waters Corporation Completes Acquisition of Light Scattering Leader Wyatt Technology

MILFORD, Mass., May 17, 2023 /PRNewswire/ -- Waters™ Corporation (NYSE: WAT) today announced it has completed its acquisition of Wyatt Technology, a pioneer and well-recognized leader in innovative light scattering and field-flow fractionation instruments, software, accessories, and services. Wi...

2023-05-17 04:15 5714

Boan Biotech's BA1202 Approved for Clinical Trial

-The First Novel CEA/CD3 Bispecific Antibody in China- YANTAI, China, May 16, 2023 /PRNewswire/ -- Boan Biotech announced today that its BA1202, a CEACAM5 (CEA)/CD3 bispecific antibody, has been approved for a clinical trial by the Center for Drug Evaluation ofChina's National Medical Products A...

2023-05-16 22:02 5278

DxVx appoints Yong Gu Lee as new CEO and Kevin Kwon as the new president

- Reorganizing the global sales networks and enhancing its capabilities to get global approvals for new drug - Accelerating value of the new drug pipelines SEOUL, South Korea, May 16, 2023 /PRNewswire/ -- DxVx announced on the 16th, the board of directors appointedYong Gu Lee as the new CEO and ...

2023-05-16 21:00 2472

DxVx appoints Yong Gu Lee as new CEO and Kevin Kwon as the new president

NCCN Global Policy Leader Named Co-Chair of Global Health Council Roundtable Advancing International Coordination in Cancer Care

Katy Winckworth-Prejsnar, Senior Manager of Global Policy and Strategic Alliances for National Comprehensive Cancer Network, to Co-Chair Non-Communicable Diseases Roundtable PLYMOUTH MEETING, Pa., May 16, 2023 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) today announced the...

2023-05-16 20:37 1823

NCCN Global Policy Leader Named Co-Chair of Global Health Council Roundtable Advancing International Coordination in Cancer Care

MediBeacon Inc. Appoints Dr. Steve Miller as Chief Medical Officer

MediBeacon expands management team as enrollment in Phase 3 study focused on kidney disease is completed ST. LOUIS, May 16, 2023 /PRNewswire/ -- MediBeacon Inc., a portfolio company within the Pansend Life Sciences segment of INNOVATE Corp. (NYSE: VATE), today announced the appointment of Dr.Ste...

2023-05-16 19:00 2077

YS Biopharma's PIKA Rabies Vaccine Receives Phase 3 Clinical Trial Approval in Pakistan

GAITHERSBURG, Md., May 16, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and commercializing new generations of vaccines and therapeutic biologics for infectious d...

2023-05-16 19:00 1963

Cambrex Completes Expansion of Snapdragon Chemistry Facility in Waltham, Massachusetts

EAST RUTHERFORD, N.J., May 16, 2023 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle, today announced that Snapdragon Chemistry has completed the se...

2023-05-16 18:00 2197

1 ... 67 68 697071 72 73 ... 382